Treatment of Melioidosis
For adults with melioidosis, initiate intravenous meropenem or imipenem for at least 14 days (intensive phase), followed by oral trimethoprim-sulfamethoxazole for 3-6 months (eradication phase) to prevent both mortality and the 13% relapse rate. 1, 2
Intensive Phase: Intravenous Therapy
First-Line Treatment
- Meropenem or imipenem are the preferred agents, demonstrating superior clinical outcomes compared to ceftazidime in severe melioidosis 1, 2
- Administer for a minimum of 14 days intravenously 1, 2
- All B. pseudomallei isolates show consistent susceptibility to carbapenems 1, 2
Alternative for Intensive Phase
- Ceftazidime 100 mg/kg/day is acceptable if carbapenems are unavailable, though associated with inferior outcomes in severe disease 1, 2
Extended Intensive Phase Duration (4-8 weeks or longer)
Extend treatment for patients with: 1, 2
- Critical illness or septic shock
- Extensive pulmonary disease
- Deep-seated collections or organ abscesses
- Osteomyelitis or septic arthritis
- Central nervous system involvement
Special Considerations During Intensive Phase
- For CNS involvement: Add trimethoprim-sulfamethoxazole 8/40 mg/kg IV/PO every 12 hours (up to 320/1600 mg) during the intensive phase 1, 2
- For septic shock: Consider adding G-CSF 300 mg IV for 10 days, though evidence remains limited 1, 3, 4
Eradication Phase: Oral Therapy
First-Line Treatment
- Trimethoprim-sulfamethoxazole (TMP-SMX) is the drug of choice for 3-6 months 1, 2, 3
- This prolonged duration is critical for eradicating intracellular bacteria and preventing relapse 2, 5
Weight-Based TMP-SMX Dosing
- <40 kg: 160/800 mg (1 double-strength tablet) twice daily
- 40-60 kg: 240/1200 mg (1.5 double-strength tablets) twice daily
- >60 kg: 320/1600 mg (2 double-strength tablets) twice daily
Folic Acid Supplementation
- Add folic acid 0.1 mg/kg up to 5 mg daily to prevent antifolate effects without compromising antimicrobial activity 1, 2
Evidence for TMP-SMX Monotherapy
- TMP-SMX monotherapy for 20 weeks is as effective as combination therapy with TMP-SMX plus doxycycline in preventing recurrence 2, 6
- Duration less than 12 weeks is associated with a 5.7-fold increase in relapse or death 6
Alternative Eradication Regimens
- Amoxicillin-clavulanate 20/5 mg/kg every 8 hours (maximum 1500/375 mg every 8 hours) for pregnant women, children, or patients intolerant to TMP-SMX, though significantly less effective 1, 2, 5
- Doxycycline 100 mg twice daily can be used as an alternative 1, 2
Critical Resistance Patterns to Avoid
B. pseudomallei is inherently resistant to: 1, 2, 3
- Penicillin and ampicillin
- First- and second-generation cephalosporins
- Gentamicin and streptomycin
- Polymyxin
- Ertapenem (despite being a carbapenem)
- Azithromycin and moxifloxacin
Never use ceftriaxone or cefotaxime - these are associated with higher mortality rates compared to ceftazidime 1, 2
Renal Function Adjustments
- Meropenem and imipenem require dose reduction based on creatinine clearance 1
- TMP-SMX requires dose adjustment in severe renal impairment (CrCl <30 mL/min) 1
- Monitor for hematologic toxicity with TMP-SMX in renal dysfunction, making folic acid supplementation critical 1
Post-Exposure Prophylaxis
- Administer TMP-SMX within 24 hours of exposure for post-exposure prophylaxis, particularly for immunosuppressed patients or following potential biological attack 1, 2, 3
- Animal studies demonstrate 100% survival when co-trimoxazole is administered within 24 hours post-infection 3
Common Pitfalls
- Misidentification: B. pseudomallei is often wrongly identified as Pseudomonas or other Burkholderia species by commercial identification systems 2, 4
- Inadequate duration: Treatment less than 12 weeks significantly increases relapse risk 6
- Wrong carbapenem: Ertapenem is ineffective despite being a carbapenem class drug 1, 3
- Inadequate source control: Adequate drainage of abscesses is essential for successful treatment and preventing relapse 4, 7